Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018

  • ID: 4583872
  • Report
  • 1005 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Abivax SA
  • Bristol-Myers Squibb Co
  • Gilead Sciences Inc
  • Longevity Biotech Inc
  • OyaGen Inc
  • Susavion Biosciences Inc
  • MORE
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights:

This latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 13, 45, 42, 1, 5, 106, 66 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 13, 25, 51 and 64 molecules, respectively.

Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abivax SA
  • Bristol-Myers Squibb Co
  • Gilead Sciences Inc
  • Longevity Biotech Inc
  • OyaGen Inc
  • Susavion Biosciences Inc
  • MORE
Introduction

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drug Profiles

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..4), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..5), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..6), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..7), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Advanced Genetic Systems Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aelix Therapeutics SL, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Akshaya Bio Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altor BioScience Corp, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altravax Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amarna Therapeutics BV, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by American Gene Technologies International Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amunix Operating Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Antigen Express Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aphios Corp, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Apotex Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Argos Therapeutics Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Atreca Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Auritec Pharmaceuticals Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by B Cell Design SAS, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biological Mimetics Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bionor Holding AS, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biotron Ltd, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bolder Biotechnology Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bukwang Pharm Co Ltd, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Cadila Healthcare Ltd, H1 2018

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abivax SA
  • AdAlta Ltd
  • Advanced Genetic Systems Inc
  • Aelix Therapeutics SL
  • Akshaya Bio Inc
  • Altor BioScience Corp
  • Altravax Inc
  • Amarna Therapeutics BV
  • American Gene Technologies International Inc
  • Amunix Operating Inc
  • Antigen Express Inc
  • Aphios Corp
  • Apotex Inc
  • Argos Therapeutics Inc
  • Atreca Inc
  • Auritec Pharmaceuticals Inc
  • B Cell Design SAS
  • Biological Mimetics Inc
  • Bionor Holding AS
  • Biotron Ltd
  • Bolder Biotechnology Inc
  • Bristol-Myers Squibb Co
  • Bukwang Pharm Co Ltd
  • Cadila Healthcare Ltd
  • Calimmune Inc
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • Cocrystal Pharma Inc
  • CompleGen Inc
  • Consegna Pharma Inc
  • ContraVir Pharmaceuticals Inc
  • Curevac AG
  • Cytodyn Inc
  • CytRx Corp
  • Enzo Biochem Inc
  • Excision BioTherapeutics Inc
  • FIT Biotech Oy
  • Fountain Biopharma Inc
  • Frontier Biotechnologies Inc
  • GeneCure LLC
  • Genetic Immunity Inc
  • GeoVax Labs Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Globeimmune Inc
  • GW Pharmaceuticals Plc
  • Heat Biologics Inc
  • Hoverink Biotechnologies Inc
  • iCo Therapeutics Inc
  • ID Pharma Co Ltd
  • IGXBio Inc
  • Immune Response BioPharma Inc
  • Immunocore Ltd
  • Immunotope Inc
  • Immusoft Corp
  • ImQuest Life Sciences Inc
  • InnaVirVax SA
  • Innovare R & D SA De CV
  • Innovative Targeting Solutions Inc
  • Inovio Pharmaceuticals Inc
  • Japan Tobacco Inc
  • Johnson & Johnson
  • Kainos Medicine Inc
  • Karyopharm Therapeutics Inc
  • Kymab Ltd
  • Longevity Biotech Inc
  • MacroGenics Inc
  • Medivir AB
  • Merck & Co Inc
  • Moderna Therapeutics Inc
  • Mologen AG
  • Mutabilis SA
  • Mycenax Biotech Inc
  • Mymetics Corp
  • NanoViricides Inc
  • Navigen Inc
  • NeED Pharma srl
  • New World Laboratories Inc
  • Novartis AG
  • Omeros Corp
  • Oncolys BioPharma Inc
  • Oncovir Inc
  • Orbis Biosciences Inc
  • Osel Inc
  • OyaGen Inc
  • PaxVax Inc
  • Phoenix Biotechnology Inc
  • PlantForm Corp
  • Profectus BioSciences Inc
  • ReceptoPharm Inc
  • Recombio SL
  • Relmada Therapeutics Inc
  • Resverlogix Corp
  • Rodos BioTarget GmbH
  • Samjin Pharm Co Ltd
  • Sangamo Therapeutics Inc
  • Sanofi
  • Sanofi Pasteur SA
  • Shanghai Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Spider Biotech
  • Spring Bank Pharmaceuticals Inc
  • ST Pharm Co., Ltd.
  • Starpharma Holdings Ltd
  • Susavion Biosciences Inc
  • Taiga Biotechnologies Inc
  • TaiMed Biologics Inc
  • Takara Bio Inc
  • Takeda Pharmaceutical Co Ltd
  • TechnoVax Inc
  • TeneoBio Inc
  • TheraJect Inc
  • Theratechnologies Inc
  • Theravectys SA
  • Transgene Biotek Ltd
  • TVAX Biomedical Inc
  • United Biomedical Inc
  • Vaccibody AS
  • Vault Pharma Inc
  • VG Life Sciences Inc
  • Vichem Chemie Research Ltd
  • ViiV Healthcare UK Ltd
  • Vincogen Corp
  • Viriom Inc
  • ViroStatics srl
  • XL-protein GmbH
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll